Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Background: Phase III randomized trial data have confirmed the activity for olaparib in homologous recombination repair (HRR) mutated metastatic castration-resistant prostate cancer (mCRPC) post next-generation hormonal agent (NHA) progression. Preclinical data have suggested the potential for a com...

Full description

Bibliographic Details
Main Authors:	T. Hedley Carr, Carrie Adelman, Alan Barnicle, Iwanka Kozarewa, Sally Luke, Zhongwu Lai, Sally Hollis, Brian Dougherty, Elizabeth A. Harrington, Jinyu Kang, Fred Saad, Nuria Sala, Antoine Thiery-Vuillemin, Noel W. Clarke, Darren Hodgson, J. Carl Barrett
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Cancers
Subjects:	circulating tumour DNA (ctDNA) homologous recombination repair (HRR) prostate cancer next-generation sequencing (NGS) PARP inhibition metastasis
Online Access:	https://www.mdpi.com/2072-6694/13/22/5830

Similar Items

Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC
by: Kimberly M. Burcher, et al.
Published: (2021-06-01)

IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer
by: Sophie Gilbert, et al.
Published: (2022-07-01)

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance
by: Maxime Cahuzac, et al.
Published: (2022-08-01)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01)

Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations
by: Chiao-En Wu, et al.
Published: (2021-04-01)

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
by: Baldwin P, et al.
Published: (2018-11-01)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01)

Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma
by: Sonu Kumar, et al.
Published: (2023-08-01)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01)

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
by: Steven P. Rowe, et al.
Published: (2018-10-01)

Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks
by: Yuning Jiang, et al.
Published: (2021-10-01)

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks
by: Estelle Bourbon, et al.
Published: (2021-06-01)

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress
by: Sidneia Sousa Santos, et al.
Published: (2022-06-01)

Sensitive and Specific Analyses of Colorectal Cancer Recurrence through Multiplex superRCA Mutation Detection in Blood Plasma
by: Emma Sandberg, et al.
Published: (2024-01-01)

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients
by: Paul van der Leest, et al.
Published: (2020-05-01)

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
by: Rosario Prados-Carvajal, et al.
Published: (2021-12-01)

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
by: Rugile Pikturniene, et al.
Published: (2024-03-01)

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
by: Chul Kim, et al.
Published: (2021-07-01)

Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
by: Ander Saenz-Antoñanzas, et al.
Published: (2019-07-01)

EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
by: Thang Thanh Phan, et al.
Published: (2022-08-01)

Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report
by: Tapas Ranjan Behera, et al.
Published: (2022-06-01)

Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management
by: Britney Niemann, et al.
Published: (2024-03-01)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01)

Circulating tumor DNA – A potential aid in the management of chordomas
by: Stephen C. Frederico, et al.
Published: (2022-10-01)

Liquid Biopsy &ndash; Possibilities for Monitoring&nbsp;the Therapeutic Response in Non-Small Cell Lung Cancer
by: Gabriela A. Raycheva, et al.
Published: (2021-12-01)

Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
by: Kavita Thakur, et al.
Published: (2021-07-01)

Target Recognition– and HCR Amplification–Induced In Situ Electrochemical Signal Probe Synthesis Strategy for Trace ctDNA Analysis
by: Aiting Cai, et al.
Published: (2022-11-01)

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint
by: Xiaoting Lin, et al.
Published: (2018-06-01)

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
by: Ashaar Al-Akhras, et al.
Published: (2024-01-01)

Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases
by: Simonetta Pazzaglia, et al.
Published: (2019-12-01)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
by: Giuseppe Fallara, et al.
Published: (2023-06-01)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
by: Jacob J. Adashek, et al.
Published: (2019-08-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

Combining Solid and Liquid Biopsy for Therapy Monitoring in Esophageal Cancer
by: Florian Richter, et al.
Published: (2023-06-01)

New Perspectives on the Importance of Cell-Free DNA Biology
by: Abel J. Bronkhorst, et al.
Published: (2022-09-01)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
by: Jian Pan, et al.
Published: (2022-12-01)

Novel imaging and circulating biomarkers in hepatic malignancies
by: Winter, H
Published: (2019)

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker
by: Li Li, et al.
Published: (2023-12-01)

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
by: Aakash Desai, et al.
Published: (2024-02-01)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
by: Ruchi Agashe, et al.
Published: (2020-08-01)